<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823104</url>
  </required_header>
  <id_info>
    <org_study_id>PREPS 2019 DEBOST-LEGRAND</org_study_id>
    <nct_id>NCT04823104</nct_id>
  </id_info>
  <brief_title>Optimizing Access to Care During Pregnancy in Rural Areas in a Perinatal Health Network</brief_title>
  <acronym>OPTI'SOINS</acronym>
  <official_title>Optimizing Access to Care During Pregnancy in Rural Areas in a Perinatal Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregnant women who live in rural area have fewer prenatal consultations. It has been&#xD;
      demonstrated that maternal and neonatal morbidity and mortality increase if time travel to a&#xD;
      maternity ward is longer than 30 min.&#xD;
&#xD;
      Home visitation in isolated area may improve prenatal follow-up as it gives full access to&#xD;
      women to health care professionals as well as biological and ultrasound exams without&#xD;
      travelling.&#xD;
&#xD;
      Our aim is to assess the impact of home visitation on prenatal follow-up as compared to&#xD;
      prenatal follow-up in maternity ward and in primary care.&#xD;
&#xD;
      Isolated areas will be randomized, for women living in areas included in the intervention&#xD;
      group, home visitations will be planned for prenatal follow-up. Ultrasound screening as well&#xD;
      as blood exams will be performed during home visitations. For women living in control areas,&#xD;
      they will be free to choose prenatal follow-up modalities.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adequate pregnancy follow-up according to the French recommendations</measure>
    <time_frame>9 months</time_frame>
    <description>number of consultations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adequate pregnancy follow-up according to the French recommendations</measure>
    <time_frame>9 months</time_frame>
    <description>number of ultrasound exams</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adequate pregnancy follow-up according to the French recommendations</measure>
    <time_frame>9 months</time_frame>
    <description>number of biological exams</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse maternal outcome</measure>
    <time_frame>10 months</time_frame>
    <description>gestational hypertension, gestational diabetes, post-partum hemmorage, maternal death, transfer in intensive unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse neonatal outcome</measure>
    <time_frame>9 months</time_frame>
    <description>prematurity, in utero death, small or large for gestational age, transfer in intensive unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>economic analyse of the intervention</measure>
    <time_frame>24 months</time_frame>
    <description>cost of equipment, human resources, balanced to income inherent to the project in accordance with the standards of cost budget accounting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Pregnancy</condition>
  <condition>Living in an Isolated Area</condition>
  <arm_group>
    <arm_group_label>Intervention group with home visitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pregnant women who are included in this group will be assigned an intervention by home visitation for pregnancy follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group without home visitation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>pregnant women will be free to choose their pregnancy follow-up without home visitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Home visitation</intervention_name>
    <description>Home visitation for pregnancy follow-up</description>
    <arm_group_label>Intervention group with home visitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women who live in a specific geographic area&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women who live outside the specific geographic area&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lise Laclautre</last_name>
    <phone>04 73 75 11 95</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Aura</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise laclautre</last_name>
      <phone>04 73 75 11 95</phone>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Anne LEGRAND</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marine PRANAL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Home visitation</keyword>
  <keyword>Isolated geographic area</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

